trending Market Intelligence /marketintelligence/en/news-insights/trending/gsvwneifb015jgwbelehxw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

European Medicines Agency committee recommends Pfizer's arthritis drug

Street Talk Episode 51 - Goldman Talks Libor Transition, Recent SOFR Volatility

ChangePays Although Still Underrepresented Women in the C Suite are Driving Profitability

Cable Nets For Kids Enjoy Wide Carriage On Skinny Bundles

Energy

Power Forecast Briefing: Fleet Transformation, Under-Powered Markets, and Green Energy in 2018


European Medicines Agency committee recommends Pfizer's arthritis drug

The European Medicines Agency's Committee for Medicinal Products for Human Use made a recommendation in favor of Pfizer Inc.'s Lifmior to treat rheumatoid arthritis and other forms of arthritis, as well as plaque psoriasis.

The drug is identical to Amgen's Enbrel, which was authorized in the EU in 2000. Lifmior is still subject to approval by the European Commission.